RJFSA
CBAY

Raymond James Financial Services Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-113,883
Closed -$2.69M – 3530
2023
Q4 		$2.69M Buy
113,883
+12,554
+12% +$224K ﹤0.01% 1412
2023
Q3 		$1.51M Buy
101,329
+3,434
+4% +$45.5K ﹤0.01% 1666
2023
Q2 		$1.07M Buy
97,895
+37,736
+63% +$351K ﹤0.01% 1892
2023
Q1 		$525K Buy
+60,159
New +$482K ﹤0.01% 2304
2021
Q4 		– Sell
-11,091
Closed -$40K – 3465
2021
Q3 		$40K Sell
11,091
-4,829
-30% -$19K ﹤0.01% 3201
2021
Q2 		$69K Buy
+15,920
New +$70.6K ﹤0.01% 3185
2020
Q4 		– Sell
-44,598
Closed -$323K – 3110
2020
Q3 		$323K Buy
+44,598
New +$238K ﹤0.01% 2236
2020
Q1 		– Sell
-13,238
Closed -$26K – 2906
2019
Q4 		$26K Buy
+13,238
New +$49.7K ﹤0.01% 2796
2018
Q2 		– Sell
-14,422
Closed -$187K – 2870
2018
Q1 		$187K Buy
+14,422
New +$179K ﹤0.01% 2280

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Raymond James Financial Services Advisors's CBAY Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 113,883 shares — an estimated $2.69M sold.

Raymond James Financial Services Advisors first reported a position in CBAY in Q1 2018 and held it in 9 quarters. The position peaked at $2.69M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Raymond James Financial Services Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 113,883 Cymabay Therapeutics shares in Q1 2024, an estimated $2.69M.
  • Raymond James Financial Services Advisors first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 9 quarters.
  • Raymond James Financial Services Advisors's Cymabay Therapeutics position peaked at $2.69M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.